Skip to content
Search

Latest Stories

India syringe maker boosts production to meet virus vaccine demand

INDIA's biggest syringe manufacturer is ramping up production to churn out a billion units, anticipating a surge in demand as the global race to find a coronavirus vaccine heats up.

While the focus on tackling the pandemic has mostly been on the development of vaccines, experts say medical essentials to administer them are also vital.


Hindustan Syringes -- one of the world's largest makers of the item -- said it is increasing its output of auto-disable devices (which prevent re-use) from 700 million a year to one billion by 2021 to meet the expected demand.

"Even if 60 per cent of the world's population is immunised, it would mean four to five billion syringes would be required," Hindustan Syringes managing director Rajiv Nath told AFP at their factory in northern Haryana state.

There are currently more than 30 candidate vaccines being tested on humans, with governments hoping to deploy one as soon as possible with the coronavirus wrecking lives and economies.

Shortages of PPE such as masks hampered early responses to the pandemic, and countries have now started building up their stockpile of syringes, vials and needles.

"We may have sufficient capacity for the first wave of vaccines which would only be administered to priority groups," Prashant Yadav, a healthcare supply chains expert at Harvard Medical School, said.

"(But) when we get to a large-scale vaccination in late 2021 or 2022 and the dose demand estimates would be greater than 10 billion, that's when syringe supply starts becoming a constraint."

So far, UNICEF has ordered 140 million syringes from Hindustan for COVAX, a global initiative aimed at ensuring a more equitable distribution of vaccines to poorer nations.

Much of the world's demand for syringes is expected to be met by factories in China and India.

More For You

Anil Agarwal

Vedanta Resources, which is based in the UK and owned by Indian billionaire Anil Agarwal, has been working on reducing its debt. (Photo credit: Getty Images)

Getty Images

Anil Agarwal’s Vedanta Resources signs £438 million refinancing deal

VEDANTA LTD said on Thursday that its parent company, Vedanta Resources, has signed a loan facility agreement worth up to £438 million with international banks to refinance existing debt.

The refinancing move, where old loans are replaced by new ones, often at better terms like lower interest rates, has led ratings agencies such as S&P Global Ratings and Moody's to upgrade their outlook on the company this year.

Keep ReadingShow less
Trump-Getty

Trump said that while deals are being made with some countries, others may face tariffs.

Getty Images

Trump says major trade deal with India may be finalised soon

US PRESIDENT Donald Trump on Friday said a "very big" trade deal could be finalised with India, suggesting significant movement in the ongoing negotiations between the two countries.

“We are having some great deals. We have one coming up, maybe with India. Very big one. Where we're going to open up India," Trump said at the “Big Beautiful Bill” event at the White House.

Keep ReadingShow less
Asda suffers nearly £600m loss as debt and IT costs surge

Asda co-ownerMohsin Issa. (Photo: Asda)

Asda suffers nearly £600m loss as debt and IT costs surge

ASDA, one of Britain’s largest supermarkets, has reported a pre-tax loss of £599 million for 2024, swinging sharply from a £180 million profit the previous year.

The loss comes despite total sales rising by over £1 billion to £26.8bn, as the retailer faces mounting debt costs, falling sales, and spiralling spending on a major IT overhaul, the Telegraph reported.

Keep ReadingShow less
Mounjaro

Mounjaro, or tirzepatide, is part of a new class of weight-loss medications, with trials showing patients losing an average of 20 per cent of their body weight after 72 weeks.

Reuters

Lilly to sell Mounjaro pens in India as Wegovy enters market

ELI LILLY said on Thursday that it has received approval from India's drug regulator to launch pre-filled injector pens of its weight-loss drug, Mounjaro.

The move gives the company more options to compete with Novo Nordisk, which recently launched its weight-loss drug Wegovy in the country.

Keep ReadingShow less
Grant Thornton's Anuj Chande urges UK firms to tap booming India

Anuj Chande

Grant Thornton's Anuj Chande urges UK firms to tap booming India

INDIAN companies are well placed to support the UK’s economic growth, Eastern Eye has been told by Anuj Chande, partner and head of the South Asia Business Group at Grant Thornton.

He was speaking after the publication of Grant Thornton’s India Meets Britain Tracker 2025: The latest trends in Indian investment in the UK, which was released last week. While companies in India need little encouragement to enter the UK market, the reverse is not true.

Keep ReadingShow less